An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

SUMMARY

The experimental drug used in this study is called Daratumumab.

 

The purpose of this study is to see if Daratumumab is useful for treating patients with relapsed or refractory Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), or Follicular Lymphoma (FL)Another purpose of the study is to see if certain patients respond to Daratumumab treatment better than othersThe safety of Daratumumab will also be studied.

The experimental drug used in this study is called Daratumumab.

 

The purpose of this study is to see if Daratumumab is useful for treating patients with relapsed or refractory Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), or Follicular Lymphoma (FL)Another purpose of the study is to see if certain patients respond to Daratumumab treatment better than othersThe safety of Daratumumab will also be studied.

 

There are 2 stages in this study. The 1st stage is to determine if Daratumumab may work for your type of cancer (lymphoma).  If there is possibility that Daratumumab may work, then the study will proceed to stage 2.  If not, the study will end for that cancer type.

COH Protocol Number : 15182

ClinicalTrials.gov Number : NCT02413489

Principal Investigator : Popplewell, Leslie M.D.

Sponsor : Janssen Research & Development

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Minimum Performance Status : ECOG/SWOG:1

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :